Education
About Us
Working with TipRanks
Follow Us
Equillium (EQ)
:EQ
EQ Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.36 - $2.43
Previous CloseN/A
Volume484.47K
Average Volume (3M)124.52K
Market Cap
$13.97M
Enterprise Value$4.34M
Total Cash (Recent Filing)$18.09M
Total Debt (Recent Filing)$384.00K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
May 08, 2025EPS Estimate
-0.26Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.23
Shares Outstanding35,609,905
10 Day Avg. Volume212,828
30 Day Avg. Volume124,519
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.60
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit0.11
Enterprise Value/Ebitda-0.57
Forecast
1Y Price Target
$1.00Price Target Upside156.41% Upside
Rating ConsensusHold
Number of Analyst Covering1
---
Equillium News
PremiumCompany Announcements
Equillium Reports 2024 Financials and Clinical Milestones
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessEQ reported positive topline results from a Phase 2 study of lead asset itolizumab in ulcerative colitis, demonstrating encouraging activity and being well tolerated with no notable safety signals.
Strategic FocusEQ will retain development and commercial rights for itolizumab in the US/Canada/Australia/New Zealand regions and will prioritize itolizumab as their lead asset with two key data readouts expected.
Valuation PotentialThe modest valuation for EQ at current levels, combined with positive data, successful regulatory interaction, and additional capital, could drive meaningful upside to EQ shares.
Bears Say
Clinical Trial ResultsEQ reported disappointing topline results from the Phase 3 EQUATOR study of lead asset itolizumab in front-line acute Graft-versus-Host Disease.
Financial ConcernsA financing solution remains a significant near-term overhang for EQ shares.
Regulatory ChallengesThere remains significant uncertainty regarding FDA's willingness to accept these results for the basis of an accelerated approval.
---
Ownership Overview
40.11% Insiders
2.87% Mutual Funds
19.79% Other Institutional Investors
34.82% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EQ FAQ
What was Equillium’s price range in the past 12 months?
Equillium lowest stock price was $0.36 and its highest was $2.43 in the past 12 months.
What is Equillium’s market cap?
Equillium’s market cap is $13.97M.
When is Equillium’s upcoming earnings report date?
Equillium’s upcoming earnings report date is May 08, 2025 which is in 36 days.
How were Equillium’s earnings last quarter?
Equillium released its earnings results on Mar 27, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.31 by $0.15.
Is Equillium overvalued?
According to Wall Street analysts Equillium’s price is currently Undervalued.
Does Equillium pay dividends?
Equillium does not currently pay dividends.
What is Equillium’s EPS estimate?
Equillium’s EPS estimate is -0.26.
How many shares outstanding does Equillium have?
Equillium has 35,609,905 shares outstanding.
What happened to Equillium’s price movement after its last earnings report?
Equillium reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.31. Following the earnings report the stock price went down -35.526%.
Which hedge fund is a major shareholder of Equillium?
Currently, no hedge funds are holding shares in EQ
---
Equillium Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$1.00 (156.41% Upside)
$1.00 (156.41% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 10.1%
Last 30 Days ▼ 10.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-83.03%
12-Months-Change
Fundamentals
Return on Equity
-38.75%
Trailing 12-Months
Asset Growth
-49.33%
Trailing 12-Months
Company Description
Equillium
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis. It also develops EQ101 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ102 to treat various gastrointestinal diseases. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.
---
EQ Stock 12 Month Forecast
Average Price Target
$1.00
▲(156.41% Upside)
Technical Analysis
Amicus
―
Arrowhead Pharmaceuticals
―
BioMarin Pharmaceutical
―
Vertex Pharmaceuticals
―
Ultragenyx Pharmaceutical
―
Best Analysts Covering EQ
1 Year
1 Year Success Rate
1/10 ratings generated profit
1 Year Average Return
-29.08%
reiterated a buy rating 5 months ago
Copying Dae Gon Ha's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -29.08% per trade.
---